Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506589 | 0.86 | MAP2K1 (0.36) | MAP2K1MAP2K2ALDH1A1L3MBTL1 | |
| SCHEMBL6500566 | 0.74 | KDM4E (0.52) | MAPTALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL6470420 | 0.74 | KDM4E (0.36) | MAPTALDH1A1HPGDL3MBTL1KDM4E | |
| SCHEMBL6506448 | 0.69 | MAP2K1 (0.40) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL13557943 | 0.67 | MAP2K1 (0.42) | MAP2K1MAP2K2 | |
| SCHEMBL6469895 | 0.67 | ALDH1A1 (0.51) | MAPTALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL6469734 | 0.65 | ALDH1A1 (0.43) | ALDH1A1GAAKDM4E | |
| SCHEMBL6533325 | 0.65 | KDM4E (0.41) | MAPTALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL1350856 | 0.64 | HSP90AB1 (0.46) | MAP2K1MAP2K2 | |
| SCHEMBL6498775 | 0.62 | KDM4E (0.51) | MAPTALDH1A1HPGDL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | MAP2K1 4663/4885MAP2K2 4197/4885MAPT 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.